<html lang="en" class="pb-page js" data-request-id="94d683a4e0d7a511-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d683a4e0d7a511-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/BFb2DxBpB1s-0GjJaxllFUW6GmFNC9Aa4vmuO-ATjcps74cWScV41Nu3Zo5JVJw0czpS3w6gzK_SalpCqtawVQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d683a4e0d7a511-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.9810060782237315"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="Specialties" content="Infectious Disease|Pediatrics">
<meta name="topics" content="Vaccines|Childhood Diseases|Bacterial Infections|Infectious Disease General|Global Health|Immunization">
<meta name="articleCategory" content="Research"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2013615","title":"Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers","category":"Research","type":"Original Article","topics":"Vaccines|Childhood Diseases|Bacterial Infections|Infectious Disease General|Global Health|Immunization","specialties":"Infectious Disease|Pediatrics","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-06-03T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Infectious Disease|Pediatrics\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Vaccines|Childhood Diseases|Bacterial Infections|Infectious Disease General|Global Health|Immunization\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2013615","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d683a4e0d7a511-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers"><meta name="dc.Creator" content="Milagritos D. Tapia"><meta name="dc.Creator" content="Samba O. Sow"><meta name="dc.Creator" content="Abdi Naficy"><meta name="dc.Creator" content="Fatoumata Diallo"><meta name="dc.Creator" content="Fadima C. Haidara"><meta name="dc.Creator" content="Amol Chaudhari"><meta name="dc.Creator" content="Lionel Martellet"><meta name="dc.Creator" content="Awa Traore"><meta name="dc.Creator" content="Kelly Townsend-Payne"><meta name="dc.Creator" content="Ray Borrow"><meta name="dc.Creator" content="Nancy Hosken"><meta name="dc.Creator" content="Igor Smolenov"><meta name="dc.Creator" content="Sambhaji S. Pisal"><meta name="dc.Creator" content="F. Marc LaForce"><meta name="dc.Creator" content="Rajeev M. Dhere"><meta name="dc.Creator" content="Dhananjay Kapse"><meta name="dc.Creator" content="Yuxiao Tang"><meta name="dc.Creator" content="Mark R. Alderson"><meta name="dc.Creator" content="Prasad S. Kulkarni"><meta name="dc.Description" content="Neisseria meningitidis serogroups A, B, C, W, X, and Y cause outbreaks of meningococcal disease. Quadrivalent conjugate vaccines targeting the A, C, W, and Y serogroups are available. A pentavalent..."><meta name="Description" content="Neisseria meningitidis serogroups A, B, C, W, X, and Y cause outbreaks of meningococcal disease. Quadrivalent conjugate vaccines targeting the A, C, W, and Y serogroups are available. A pentavalent..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-06-03"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2013615"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202106033842208"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2013615">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2013615">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2013615">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers | NEJM">
        <meta property="og:title" content="Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2013615">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/d0e5fe79-1afa-427e-8eb0-f919689733a0/nejmoa2013615_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/d0e5fe79-1afa-427e-8eb0-f919689733a0/nejmoa2013615_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Neisseria meningitidis serogroups A, B, C, W, X, and Y cause outbreaks of meningococcal
disease. Quadrivalent conjugate vaccines targeting the A, C, W, and Y serogroups are
available. A pentavalent...">
        <meta name="twitter:description" content="Neisseria meningitidis serogroups A, B, C, W, X, and Y cause outbreaks of meningococcal
disease. Quadrivalent conjugate vaccines targeting the A, C, W, and Y serogroups are
available. A pentavalent...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1140">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="citation_fulltext_world_readable" content="">
    <meta name="publication_doi" content="10.1056/NEJMoa2013615">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2013615">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;article:article:doi\:10.1056/NEJMoa2013615;ctype:string:Journal Content;wgroup:string:MMS NextGen Website Group;issue:issue:doi\:10.1056/nejm_2021.384.issue-22;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2013615" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2013615" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2013615" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2013615" class="inputDoi"><input type="hidden" value="M.D. Tapia and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;384:2115-2123" class="inputCitation"><input type="hidden" value="06-02-2021" class="inputEPubDate"><input type="hidden" value="June 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d683a4e0d7a511-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Milagritos D.</span> <span property="familyName">Tapia</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Samba O.</span> <span property="familyName">Sow</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Abdi</span> <span property="familyName">Naficy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fatoumata</span> <span property="familyName">Diallo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Fadima C.</span> <span property="familyName">Haidara</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Amol</span> <span property="familyName">Chaudhari</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9972-9755" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9972-9755</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lionel</span> <span property="familyName">Martellet</span>, <span property="honorificSuffix">M.A.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+11</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Awa</span> <span property="familyName">Traore</span>, <span property="honorificSuffix">Pharm.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kelly</span> <span property="familyName">Townsend-Payne</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ray</span> <span property="familyName">Borrow</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nancy</span> <span property="familyName">Hosken</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Igor</span> <span property="familyName">Smolenov</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sambhaji S.</span> <span property="familyName">Pisal</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">F. Marc</span> <span property="familyName">LaForce</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rajeev M.</span> <span property="familyName">Dhere</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Dhananjay</span> <span property="familyName">Kapse</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yuxiao</span> <span property="familyName">Tang</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark R.</span> <span property="familyName">Alderson</span>, <span property="honorificSuffix">Ph.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Prasad S.</span> <span property="familyName">Kulkarni</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-11</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">June 2, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">384</span></span>:<span property="pageStart">2115</span>-<span property="pageEnd">2123</span></div><div class="doi">DOI: 10.1056/NEJMoa2013615</div><div class="core-enumeration"><a href="/toc/nejm/384/22"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">384</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">22</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMilagritos%2BD.%2BTapia%252C%2BSamba%2BO.%2BSow%252C%2BAbdi%2BNaficy%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa2013615%26title%3DMeningococcal%2BSerogroup%2BACWYX%2BConjugate%2BVaccine%2Bin%2BMalian%2BToddlers%26publicationDate%3D06%252F03%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2013615" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DMilagritos%2BD.%2BTapia%252C%2BSamba%2BO.%2BSow%252C%2BAbdi%2BNaficy%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D384%26issueNum%3D22%26contentID%3D10.1056%252FNEJMoa2013615%26title%3DMeningococcal%2BSerogroup%2BACWYX%2BConjugate%2BVaccine%2Bin%2BMalian%2BToddlers%26publicationDate%3D06%252F03%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/f6741db8-734a-49d1-8910-64b67f15bcfc/nejmoa2013615.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2013615.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2013615" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2013615" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2013615.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph"><i>Neisseria meningitidis</i> serogroups A, B, C, W, X, and Y cause outbreaks of meningococcal disease. Quadrivalent conjugate vaccines targeting the A, C, W, and Y serogroups are available. A pentavalent vaccine that also includes serogroup X (NmCV-5) is under development.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a phase 2, observer-blinded, randomized, controlled trial involving Malian children 12 to 16 months of age. Participants were assigned in a 2:2:1 ratio to receive nonadjuvanted NmCV-5, alum-adjuvanted NmCV-5, or the quadrivalent vaccine MenACWY-D, administered intramuscularly in two doses 12 weeks apart. Participants were followed for safety for 169 days. Immunogenicity was assessed with an assay for serum bactericidal antibody (SBA) with rabbit complement on days 0, 28, 84, and 112.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 376 participants underwent randomization, with 150 assigned to each NmCV-5 group and 76 to the MenACWY-D group; 362 participants received both doses of vaccine. A total of 1% of the participants in the nonadjuvanted NmCV-5 group, 1% of those in the adjuvanted NmCV-5 group, and 4% of those in the MenACWY-D group reported local solicited adverse events; 6%, 5%, and 7% of the participants, respectively, reported systemic solicited adverse events. An SBA titer of at least 128 was seen in 91 to 100% (for all five serotypes) of the participants in the NmCV-5 groups and in 36 to 99% (excluding serogroup X) of those in the MenACWY-D group at day 84 (before the second dose); the same threshold was met in 99 to 100% (for all five serotypes) of the participants in the NmCV-5 groups and in 92 to 100% (excluding serogroup X) of those in the MenACWY-D group at day 112. Immune responses to the nonadjuvanted and adjuvanted NmCV-5 formulations were similar.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">No safety concerns were identified with two doses of NmCV-5. A single dose of NmCV-5 elicited immune responses that were similar to those observed with two doses of MenACWY-D. Adjuvanted NmCV-5 provided no discernible benefit over nonadjuvanted NmCV-5. (Funded by the U.K. Foreign, Commonwealth, and Development Office; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03295318" target="_blank">NCT03295318</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph"><i>Neisseria meningitidis</i> is known to cause outbreaks of meningitis in many parts of the world. The sub-Saharan African meningitis belt, which stretches from Senegal to Ethiopia, has the highest annual incidence of invasive meningococcal disease, with outbreaks occurring on an annual basis and with recurrent large epidemics every 7 to 14 years.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3" href-manipulated="true">1-3</a></sup> Among the several serogroups that have been classified on the basis of their polysaccharide capsule structure, six (A, B, C, W, X, and Y) are known to cause most cases of invasive disease. The serogroup distribution varies regionally, with serotypes A, C, and W being the most common in sub-Saharan Africa until recently. A proportional increase in the incidence of serogroup X disease has been reported, with an increase from 3% of 4150 confirmed meningitis cases during the period from 2013 through 2016 to 22% of 1410 cases in 2017, mainly in Burkina Faso, Niger, and Togo.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5" id="body-ref-r5" href-manipulated="true">4,5</a></sup></div><div role="paragraph">The two serious manifestations of invasive meningococcal disease are meningitis and septicemia, which can be fatal in 50% of cases if untreated. Even when meningococcal disease is treated, mortality is approximately 10%. Among survivors, 10 to 20% have sequelae such as severe permanent brain damage, mental retardation, deafness, epilepsy, and other neurologic disorders.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1" id="body-ref-r1-2" href-manipulated="true" aria-label="Reference 1">1</a></sup></div><div role="paragraph">To tackle the problem of large epidemics of serogroup A disease in the meningitis belt, MenAfriVac, a meningococcal A conjugate vaccine, was developed in a partnership involving the Serum Institute of India, the World Health Organization, and PATH, with funding from the Bill and Melinda Gates Foundation.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6" href-manipulated="true" aria-label="Reference 6">6</a></sup> MenAfriVac has been used extensively in mass immunization campaigns and has virtually eliminated serogroup A disease from the meningitis belt<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8" href-manipulated="true">7,8</a></sup>; however, other serogroups, such as C, W, and X, continue to be reported.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9 r10 r11 r12" id="body-ref-r12" href-manipulated="true">9-12</a></sup></div><div role="paragraph">Currently, three A, C, W, and Y meningococcal conjugate vaccines are commercially available (Menactra, Menveo, and Nimenrix)<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13" href-manipulated="true" aria-label="Reference 13">13</a></sup>; however, no licensed vaccine includes serogroup X. Therefore, a pentavalent meningococcal conjugate vaccine incorporating the A, C, W, Y, and X serogroups (NmCV-5) was developed by the Serum Institute of India in partnership with PATH. In a phase 1 clinical study involving healthy adults in the United States, two formulations of NmCV-5 (with and without adjuvant) showed an acceptable safety profile and encouraging immunogenicity.<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14" id="body-ref-r14" href-manipulated="true" aria-label="Reference 14">14</a></sup> Given these results, we conducted a phase 2 trial involving Malian toddlers to assess the safety and immunogenicity of this vaccine in this age group, to determine the need for an adjuvant in the formulation, and to determine whether one or two doses would be needed to elicit immune responses.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">We conducted a phase 2 randomized, controlled, observer-blinded, single-center trial involving healthy Malian children 12 to 16 months of age. The trial was designated to be observer-blinded, which meant that the vaccine preparation and administration in masked syringes were handled by site staff who were aware of the trial group assignments but did not participate in any of the clinical trial evaluations. The parents or legal guardians of the participants, the site staff involved in the evaluation of trial end points, and the laboratory staff who performed the immunogenicity assays were unaware of which trial vaccine was administered to each participant. Full details of the trial design are provided in the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org.</div><div role="paragraph">The trial was approved by the research ethics committee of the Faculté de Médecine, de Pharmacie et d’Odonto-Stomatologie, Bamako, Mali, and by the institutional review board of the University of Maryland, Baltimore. The trial was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonisation and the principles of the Declaration of Helsinki. Full written informed consent was provided by each participant’s parent or legal guardian before enrollment. An independent data and safety monitoring board was constituted to assess the safety of the vaccines during the trial.</div></section><section id="sec-1-2"><h3>Trial Population</h3><div role="paragraph">Children 12 to 16 months of age were recruited from the urban Bamako area. Children were excluded from the trial if they had a history of any meningococcal vaccination or disease or had had any intimate contact with a person with meningococcal infection in the previous 60 days. Other major exclusion criteria were a history of hypersensitivity to any of the vaccine components, any clinically significant disorders, immune deficiency, malnutrition, known hepatitis B or C, human immunodeficiency virus infection, or malaria at the time of vaccination.</div></section><section id="sec-1-3"><h3>Trial Vaccines</h3><div role="paragraph">NmCV-5 is a lyophilized powder containing meningococcal serogroup A and X polysaccharides conjugated to tetanus toxoid and meningococcal serogroup C, W, and Y polysaccharides conjugated to recombinant CRM197 (cross-reactive material 197, a nontoxic mutant of diphtheria toxin) protein. The vaccine was reconstituted with either normal saline (nonadjuvanted formulation) or with normal saline containing aluminum phosphate (adjuvanted formulation) just before administration. After reconstitution, each 0.5-ml dose of NmCV-5 contained 5 μg each of the meningococcal serogroup A, C, W, Y, and X polysaccharides. The licensed MenACWY-D conjugate vaccine (Menactra, Sanofi Pasteur) was supplied as a single 0.5-ml dose that contained 4 μg each of the meningococcal serogroup A, C, W, and Y polysaccharides conjugated to diphtheria toxoid.</div></section><section id="sec-1-4"><h3>Objectives and Procedures</h3><div role="paragraph">The primary objective was to assess severe reactogenicity (i.e., grade 3 local and systemic solicited adverse events) of the nonadjuvanted and adjuvanted formulations of NmCV-5 as compared with MenACWY-D. The secondary objectives were to assess safety further (all other grades of solicited adverse events, unsolicited adverse events, adverse events that led to withdrawal from the trial, and serious adverse events) and to assess the immunogenicity of the two NmCV-5 formulations as compared with MenACWY-D.</div><div role="paragraph">The participants visited the trial clinic on day 0 (baseline) and on days 7, 28, 84, 91, 112, and 168. On day 0, eligible participants were randomly assigned, in a 2:2:1 ratio, to receive two doses of nonadjuvanted NmCV-5, adjuvanted NmCV-5, or MenACWY-D. Two doses of each vaccine were to be administered intramuscularly, with the first injection on day 0 and the second on day 84.</div><div role="paragraph">Local and systemic solicited adverse events occurring within 7 days after each vaccination were assessed daily by site staff and recorded in the home-visit worksheets. Data on unsolicited adverse events with an onset within 28 days after each vaccination were collected weekly by site staff during home and site visits. Data on serious adverse events and adverse events that led to withdrawal from the trial were collected during the entire trial period.</div><div role="paragraph">Solicited local adverse events included tenderness and swelling or induration at the injection site. Solicited systemic adverse events included irritability, drowsiness, decreased eating, vomiting, and fever. Secondary safety end points were mild and moderate grades of solicited adverse events with an onset during the 7 days after each vaccination, unsolicited adverse events with an onset during the 28 days after each vaccination, and serious adverse events and adverse events leading to premature withdrawal from the trial. The severity of all adverse events was graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.1.</div><div role="paragraph">For the assessment of secondary immunogenicity end points, approximately 5 ml of blood was obtained from the participant just before each vaccination (on days 0 and 84) and at 28 days after each vaccination (on days 28 and 112). The serum samples were tested with an assay for the serum bactericidal antibody (SBA) with baby rabbit complement at the central Public Health England laboratory (Manchester, United Kingdom) to measure functional antibodies against meningococcal serogroups A, C, W, Y, and X.<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15" id="body-ref-r15" href-manipulated="true" aria-label="Reference 15">15</a></sup></div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">We calculated that the enrollment of 375 participants (150 participants in each NmCV-5 group and 75 participants in the MenACWY-D group) would provide the trial with 80% power to detect a difference of 15.4 percentage points in the incidence of severe solicited adverse events between each NmCV-5 group and the MenACWY-D group, with the use of Fisher’s exact test at a significance level of 0.05, under the assumption that the incidence of severe reactions would be 5% in the MenACWY-D group and that 10% of the participants would withdraw from the trial. The percentage of participants who had at least one severe solicited adverse event within 7 days after any trial vaccination (in the periods of days 0 to 6 and days 84 to 90) was the primary safety end point to be compared between each NmCV-5 group and the MenACWY-D control group in a descriptive manner. The safety population included all the participants who were enrolled, received at least one dose of trial vaccine, and had any safety data available. The between-group differences in the percentages were provided, along with two-sided 95% confidence intervals obtained by the Miettinen and Nurminen method<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16" id="body-ref-r16" href-manipulated="true" aria-label="Reference 16">16</a></sup>; similar analyses were conducted for all applicable secondary end points.</div><div role="paragraph">The comparisons of immunogenicity between the NmCV-5 groups and the MenACWY-D group and between the nonadjuvanted NmCV-5 group and the adjuvanted NmCV-5 group were performed with the use of a noninferiority method. Noninferiority was assessed by examining whether the lower limit of the 95% confidence interval for the between-group difference in percentages was above −10 percentage points (a commonly accepted noninferiority margin) for each serogroup (A, C, W, Y, and X). The immunogenicity analysis was performed in the per-protocol population, which included all the participants who correctly received their assigned trial vaccine with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment and who provided, at least at one time point after vaccination, a serum sample that could be evaluated. A supportive analysis of immunogenicity was also conducted in the full analysis population, which included all the participants who underwent randomization, received at least one dose of trial vaccine, and provided, at least at one time point after vaccination, a serum sample that could be evaluated; this analysis was conducted according to randomly assigned trial group.</div><div role="paragraph">The immunogenicity analyses in each group included the geometric mean titer (GMT) of SBA for each meningococcal serogroup (A, C, W, Y, and X) at day 0 (prevaccination baseline value) and at days 28, 84, and 112. The percentages of participants with SBA titers of at least 128 at each of these trial days were calculated, as were the percentages of participants who had an increase of at least 4 times the baseline SBA titers (i.e., among participants with a prevaccination SBA titer of &lt;8, a postvaccination titer of ≥32; among participants with a prevaccination SBA titer of ≥8, a postvaccination titer of ≥4 times the prevaccination titer) that were obtained at days 28 and 112 (i.e., 4 weeks after each vaccination).</div><div role="paragraph">The exact two-sided 95% confidence intervals for the percentages were calculated by means of the Clopper–Pearson method for all applicable end points. The GMTs were provided, with two-sided 95% confidence intervals, by exponentiation of the corresponding means of log<sub>2</sub>-transformed SBA titers and their 95% confidence intervals. Missing values were treated as missing at random. A post hoc sensitivity analysis was performed to examine the effect of missing data. The last-observation-carried-forward and worst-case methods were used to impute missing data for the primary end point. For immunogenicity end points, the mean value and worst-case methods were used for imputation. All the statistical analyses were performed with the use of SAS software, version 9.3 (SAS Institute).</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Trial Population</h3><div role="paragraph">The trial was conducted from November 2017 through August 2018. Among the 379 children who underwent screening, 2 had a screening failure and 1 had early withdrawal of informed consent. Therefore, 376 participants underwent randomization; 150 children were assigned to each of the NmCV-5 groups and 76 to the MenACWY-D group. Informed consent was withdrawn before the receipt of the first dose for 1 participant who had been assigned to the nonadjuvanted NmCV-5 group. The remaining 375 participants received the first dose of trial vaccine, 362 received the second dose, and 360 completed the trial. Among the participants who received any dose of vaccine, 15 discontinued or withdrew from the trial; 3 discontinuations were due to death, 10 due to protocol deviations, 1 due to withdrawal of informed consent, and 1 due to travel. At the end of the trial, there were 375 participants in the safety population and 360 in the per-protocol population (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org).</div><div role="paragraph">All the participants were Black African, and there was a slight preponderance of male participants in each trial group (range, 51 to 55%). Overall, the mean age of the participants was 12.1 months, and the median age was 12.0 months. The distributions of length (mean [±SD], 72.9±2.7 cm) and weight (mean, 8.8±1.1 kg) were similar across all three groups.</div></section><section id="sec-2-2"><h3>Safety Results</h3><div role="paragraph">No immediate adverse events were reported within 30 minutes after vaccination. None of the participants had any severe solicited adverse events. After the first vaccine dose, 1 of 149 participants (1%) in the nonadjuvanted NmCV-5 group, 2 of 150 (1%) in the adjuvanted NmCV-5 group, and 3 of 76 (4%) in the MenACWY-D group had at least one local solicited adverse event. No local solicited adverse events were reported after the second dose.</div><div role="paragraph">Overall, 6% of the participants in the nonadjuvanted NmCV-5 group, 5% of those in the adjuvanted NmCV-5 group, and 7% of those in the MenACWY-D group reported systemic solicited adverse events. Systemic solicited adverse events were reported after the first dose in 8 of 149 participants (5%) in the nonadjuvanted NmCV-5 group, in 6 of 150 (4%) in the adjuvanted NmCV-5 group, and in 3 of 76 (4%) in the MenACWY-D group; systemic solicited adverse events after the second dose were reported in 1 of 144 participants (1%), in 2 of 145 (1%), and in 2 of 73 (3%), respectively. Only fever and vomiting were reported as solicited adverse events after the second dose. Other than two events of fever of moderate severity (one each in the nonadjuvanted NmCV-5 group and the adjuvanted NmCV-5 group), all the solicited adverse events were mild in severity (Table S1).</div><div role="paragraph">During the 28 days after receipt of the first dose, 37 of 149 participants (25%) in the nonadjuvanted NmCV-5 group, 39 of 150 (26%) in the adjuvanted NmCV-5 group, and 23 of 76 (30%) in the MenACWY-D group reported 48, 46, and 28 unsolicited adverse events, respectively. None of these 122 adverse events, other than 2 events of diarrhea in participants in the nonadjuvanted NmCV-5 group, were assessed by the investigator as being related to a trial vaccine.</div><div role="paragraph">During the 28 days after receipt of the second dose, 23 of 144 participants (16%) in the nonadjuvanted NmCV-5 group, 17 of 145 (12%) in the adjuvanted NmCV-5 group, and 16 of 73 (22%) in the MenACWY-D group reported 24, 17, and 17 unsolicited adverse events, respectively. None of these 58 adverse events were assessed by the investigator as being related to a trial vaccine.</div><div role="paragraph">Almost all the unsolicited adverse events that were reported during the trial were respiratory tract infections, gastroenteritis, or diarrhea. All the unsolicited adverse events were mild or moderate in severity, and all resolved without any sequelae (Table S2).</div><div role="paragraph">Three serious adverse events, one in each group, occurred during the trial, and all led to death. These events were pneumonia (in the nonadjuvanted NmCV-5 group), <i>Escherichia coli</i> sepsis (in the adjuvanted NmCV-5 group), and second-degree burns (in the MenACWY-D group). All three serious adverse events were assessed by the investigator as being unrelated to a trial vaccine (Table S3).</div></section><section id="sec-2-3"><h3>Immunogenicity Results</h3><div role="paragraph">The SBA GMTs for each meningococcal serogroup in the per-protocol population are presented in <a href="#f1">Figure 1</a> and Table S4. The GMTs at baseline (day 0) were low (≤4.4) across all three trial groups. At all subsequent time points and for all serogroups, the GMTs were higher in both the nonadjuvanted NmCV-5 group and the adjuvanted NmCV-5 group than in the MenACWY-D group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2013615_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2013615_f1.jpg"><img src="/cms/10.1056/NEJMoa2013615/asset/d0e5fe79-1afa-427e-8eb0-f919689733a0/assets/images/large/nejmoa2013615_f1.jpg" height="1140" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Geometric Mean Titers of Serum Bactericidal Antibody, According to Meningococcal Serogroup (Per-Protocol Population).</div><div class="notes"><div role="doc-footnote">Shown are the geometric mean titers and 95% confidence intervals (𝙸 bars) of the serum bactericidal antibody with baby rabbit complement that were observed in participants who received nonadjuvanted NmCV-5, adjuvanted NmCV-5, or MenACWY-D at baseline (day 0), at 28 days and 84 days after receipt of the first dose (days 28 and 84), and at 28 days after receipt of the second dose (day 112). The per-protocol population included all the participants who correctly received their assigned trial vaccine with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the trial vaccines and who provided, at least at one time point after vaccination, a serum sample that could be evaluated.</div></div></figcaption></figure></div><div role="paragraph">At 84 days after receipt of the first dose, the GMTs were proportionally reduced from those at 28 days after receipt of the first dose for all serogroups in both the NmCV-5 groups and the MenACWY-D group. GMTs were higher at 28 days after receipt of the first dose of either formulation of NmCV-5 than they were 28 days after receipt of the second dose of MenACWY-D, despite an increase in the GMTs after the second dose of MenACWY-D.</div><div role="paragraph">At baseline, for all five serogroups, 15% or less of the participants in each of the three groups had an SBA titer of at least 128 (<a href="#t1">Table 1</a>). At 28 days after receipt of the first dose, 97% or more of the participants (lowest lower boundary of the 95% confidence interval [CI], 93.0) in the two NmCV-5 groups had SBA titers of at least 128 against all five serogroups, whereas in the MenACWY-D group, SBA titers of at least 128 in at least 90% of participants were limited to serogroups A and W. The response in the MenACWY-D group against serogroup C was 54% (95% CI, 42 to 66), whereas it was 99% (95% CI, 95 to &gt;99) in the nonadjuvanted NmCV-5 group.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t1.jpg"><img src="/cms/10.1056/NEJMoa2013615/asset/b1d0ba86-bc2e-4fa6-9f2a-d19f2fd0ecf2/assets/images/large/nejmoa2013615_t1.jpg" height="2056" width="1712" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Day and Serogroup</th><th class="txxx-borders" colspan="2"><span>Nonadjuvanted NmCV-5<br>(N=144)</span></th><th class="txxx-borders" colspan="2"><span>Adjuvanted NmCV-5<br>(N=144)</span></th><th class="txxr-borders" colspan="2"><span>MenACWY-D<br>(N=72)</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxr-borders">% (95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 0</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">16</td><td class="xxxx-borders">11 (6 to 17)</td><td class="xxxx-borders">18</td><td class="xxxx-borders">12 (8 to 19)</td><td class="xxxx-borders">10</td><td class="xxxr-borders">14 (7 to 24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1 (&lt;1 to 5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0 (0 to 3)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0 (0 to 5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">8</td><td class="xxxx-borders">6 (2 to 11)</td><td class="xxxx-borders">5</td><td class="xxxx-borders">3 (1 to 8)</td><td class="xxxx-borders">2</td><td class="xxxr-borders">3 (&lt;1 to 10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">16</td><td class="xxxx-borders shading">11 (6 to 17)</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">15 (9 to 21)</td><td class="xxxx-borders shading">10</td><td class="xxxr-borders shading">14 (7 to 24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">15</td><td class="xxxx-borders">10 (6 to 17)</td><td class="xxxx-borders">12</td><td class="xxxx-borders">8 (4 to 14)</td><td class="xxxx-borders">6</td><td class="xxxr-borders">8 (3 to 17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 28</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">140</td><td class="xxxx-borders shading">97 (93 to 99)</td><td class="xxxx-borders shading">39</td><td class="xxxr-borders shading">54 (42 to 66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">142</td><td class="xxxx-borders">99 (95 to &gt;99)</td><td class="xxxx-borders">141</td><td class="xxxx-borders">98 (94 to &gt;99)</td><td class="xxxx-borders">65</td><td class="xxxr-borders">90 (81 to 96)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">140</td><td class="xxxx-borders shading">97 (93 to 99)</td><td class="xxxx-borders shading">143</td><td class="xxxx-borders shading">99 (96 to &gt;99)</td><td class="xxxx-borders shading">64</td><td class="xxxr-borders shading">89 (79 to 95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">15</td><td class="xxxr-borders">21 (12 to 32)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 84</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">133</td><td class="xxxx-borders shading">92 (87 to 96)</td><td class="xxxx-borders shading">131</td><td class="xxxx-borders shading">91 (85 to 95)</td><td class="xxxx-borders shading">26</td><td class="xxxr-borders shading">36 (25 to 48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">137</td><td class="xxxx-borders">95 (90 to 98)</td><td class="xxxx-borders">139</td><td class="xxxx-borders">97 (92 to 99)</td><td class="xxxx-borders">57</td><td class="xxxr-borders">79 (68 to 88)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">138</td><td class="xxxx-borders shading">96 (91 to 98)</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">98 (94 to &gt;99)</td><td class="xxxx-borders shading">60</td><td class="xxxr-borders shading">83 (73 to 91)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">14</td><td class="xxxr-borders">19 (11 to 30)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 112</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">72</td><td class="xxxr-borders">100 (95 to 100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">68</td><td class="xxxr-borders shading">94 (86 to 98)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">69</td><td class="xxxr-borders">96 (88 to 99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">66</td><td class="xxxr-borders shading">92 (83 to 97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">X</td><td class="xbxx-borders">143</td><td class="xbxx-borders">99 (96 to &gt;99)</td><td class="xbxx-borders">144</td><td class="xbxx-borders">100 (97 to 100)</td><td class="xbxx-borders">22</td><td class="xbxr-borders">31 (20 to 43)</td></tr></tbody></table></div><figcaption><div class="caption">Participants with Serum Bactericidal Antibody Titers of at Least 128 at Days 0, 28, 84, and 112 (Per-Protocol Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The titers of serum bactericidal antibody with rabbit complement were assessed at baseline (day 0), at 28 days and 84 days after receipt of the first dose (days 28 and 84), and 28 days after receipt of the second dose (day 112). The per-protocol population included all the participants who correctly received their assigned trial vaccine with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment and who provided, at least at one time point after vaccination, a serum sample that could be evaluated. For percentage calculations, the denominator is the number of participants with nonmissing values at baseline and postvaccination visits. Data were missing at day 0 for serogroup C in 1 participant in the nonadjuvanted NmCV-5 group and for serogroup W in 1 participant in each NmCV-5 group. CI denotes confidence interval.</div></div></div></figcaption></figure></div><div role="paragraph">Just before the receipt of the second dose (at day 84), at least 91% of the participants in the two NmCV-5 groups still had SBA titers of at least 128 against all five serogroups. In the MenACWY-D group, this threshold (≥128) was maintained in more than 90% of participants only for serogroup A; for serogroup C, 36% of the participants (95% CI, 25 to 48) had an SBA titer of at least 128.</div><div role="paragraph">At 28 days after receipt of the second dose (day 112), at least 99% of the participants in the two NmCV-5 groups had an SBA titer of at least 128 against all five serogroups. In the MenACWY-D group, this threshold was met in at least 91% of the participants for serogroups A, C, W, and Y.</div><div role="paragraph">At 28 days after receipt of the first vaccine dose, 97% or more of the participants (lowest lower boundary of the 95% CI, 93) in each NmCV-5 group had a minimum increase of 4 times the baseline SBA titers against all five serogroups, whereas in the MenACWY-D group a minimum increase of 4 times the baseline SBA titers was observed in at least 90% of the participants only for serogroups A and W and was observed in 69% of the participants (95% CI, 58 to 80) for serogroup C (<a href="#t2">Table 2</a>). At the day 112 visit, which was scheduled to be 28 days after receipt of the second vaccine dose, more than 98% of the participants in all three groups had a minimum increase of 4 times the baseline SBA titers against all the serogroups included in the respective vaccines.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t2.jpg"><img src="/cms/10.1056/NEJMoa2013615/asset/c5842390-5bbd-4dfb-9601-8fe20b6a3ea7/assets/images/large/nejmoa2013615_t2.jpg" height="1289" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Day and Serogroup</th><th class="txxx-borders" colspan="2"><span>Nonadjuvanted NmCV-5<br>(N=144)</span></th><th class="txxx-borders" colspan="2"><span>Adjuvanted NmCV-5<br>(N=144)</span></th><th class="txxr-borders" colspan="2"><span>MenACWY-D<br>(N=72)</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxr-borders">% (95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 28</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">70</td><td class="xxxr-borders">97 (90 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">98 (94 to &gt;99)</td><td class="xxxx-borders shading">50</td><td class="xxxr-borders shading">69 (57 to 80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">140</td><td class="xxxx-borders">98 (94 to &gt;99)</td><td class="xxxx-borders">140</td><td class="xxxx-borders">98 (94 to &gt;99)</td><td class="xxxx-borders">65</td><td class="xxxr-borders">90 (81 to 96)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">140</td><td class="xxxx-borders shading">97 (93 to 99)</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">63</td><td class="xxxr-borders shading">88 (78 to 94)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">142</td><td class="xxxx-borders">99 (95 to &gt;99)</td><td class="xxxx-borders">12</td><td class="xxxr-borders">17 (9 to 27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 112</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (96 to &gt;99)</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">72</td><td class="xxxr-borders shading">100 (95 to 100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">142</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">71</td><td class="xxxr-borders shading">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">X</td><td class="xbxx-borders">143</td><td class="xbxx-borders">99 (96 to &gt;99)</td><td class="xbxx-borders">143</td><td class="xbxx-borders">99 (96 to &gt;99)</td><td class="xbxx-borders">19</td><td class="xbxr-borders">26 (17 to 38)</td></tr></tbody></table></div><figcaption><div class="caption">Participants with an Increase in Serum Bactericidal Antibody Titers of at Least 4 Times the Baseline Value on Days 28 and 112 (Per-Protocol Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">A serum bactericidal antibody titer of at least 4 times the baseline value was defined as follows: a postvaccination titer of at least 32 in participants with a prevaccination titer of less than 8, and a postvaccination titer of at least 4 times the prevaccination titer in participants with a prevaccination titer of 8 or higher. For percentage calculations, the denominator is the number of participants with nonmissing values at baseline and postvaccination visits. Data were missing at days 28 and 112 for serogroup C in 1 participant in the nonadjuvanted NmCV-5 group and for serogroup W in 1 participant in each NmCV-5 group.</div></div></div></figcaption></figure></div><div role="paragraph">There were no notable differences between the nonadjuvanted NmCV-5 group and the adjuvanted NmCV-5 group for any serogroup and at any time point with regard to the percentage of participants with SBA titers of at least 128 (<a href="#t1">Table 1</a>) or the percentage of participants with a minimum increase of 4 times the baseline SBA titers (<a href="#t2">Table 2</a>) after each trial vaccination. For the percentage of participants with SBA titers of at least 128 for all five serogroups on days 28, 84, and 112, the lowest lower boundary of the 95% confidence intervals for the between-group differences (between each of the NmCV-5 groups and the MenACWY-D group) was −3 percentage points. For the percentage of participants who had an increase of at least 4 times the baseline titer for all five serogroups on days 28 and 112, the lowest lower boundary of the 95% confidence intervals for the between-group differences was −4 percentage points. The immunogenicity results in the full analysis population (369 participants) did not differ substantially from those in the per-protocol population (360 participants). The primary safety end-point results and immunogenicity results from the post hoc sensitivity analysis were similar to those observed in the planned analysis.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">This phase 2 trial involving Malian toddlers was conducted to assess the safety and immunogenicity of nonadjuvanted and adjuvanted formulations of NmCV-5 as compared with MenACWY-D. The local reactogenicity profiles of the two NmCV-5 formulations were similar to that of MenACWY-D, and no safety concerns were identified.</div><div role="paragraph">The currently licensed polyvalent meningococcal conjugate vaccines for children younger than 2 years of age (Menactra, Menveo, and Nimenrix) do not contain any adjuvant.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r18 r19" id="body-ref-r19-1" href-manipulated="true">17-19</a></sup> This trial showed that NmCV-5 also does not need an adjuvant, because both formulations elicited similar immune responses to all serogroups at all time points.</div><div role="paragraph">MenACWY-D is recommended at a two-dose schedule in children 9 through 23 months of age,<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17" id="body-ref-r17-2" href-manipulated="true" aria-label="Reference 17">17</a></sup> and the findings of this trial support this schedule. In contrast, a single dose of NmCV-5 elicited immune responses that were similar to or higher than those observed with the two-dose schedule of MenACWY-D, which indicates that a single dose of NmCV-5 may protect children who receive the vaccine at 12 through 16 months of age. For this age group, Menveo, which is conjugated to CRM197, is recommended at a two-dose schedule and Nimenrix, which is conjugated to tetanus toxoid, at a one-dose schedule.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r19" id="body-ref-r19-2" href-manipulated="true">18,19</a></sup> Menactra is conjugated to diphtheria toxoid. The single-dose schedule of NmCV-5 is an important consideration in the sub-Saharan African meningitis belt, given considerations of cost and the issues involved in having people return for a second vaccine dose.</div><div role="paragraph">NmCV-5 was immunogenic for serogroup X, which is an important observation because there is no currently licensed vaccine against serogroup X. In the past two decades, the incidence of serogroup X disease has increased in the meningitis belt, so an X-containing vaccine has a potential benefit over existing meningococcal conjugate vaccines.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20" href-manipulated="true" aria-label="Reference 20">20</a></sup> The MenACWY-D group also had small increases in responses against serogroup X. Possible explanations include subclinical infections with serogroup X or cross-reactive antibodies.</div><div role="paragraph">At 3 months after the first dose (day 84), the percentage of participants in the two NmCV-5 groups who had SBA titers of at least 128 was at least 91% for all five serogroups. By comparison, the same threshold was maintained in 36% of the participants in the MenACWY-D group for serogroup C. The SBA GMTs also remained high 3 months after receipt of the first dose of NmCV-5.</div><div role="paragraph">For the percentage of participants with SBA titers of at least 128 for all five serogroups on days 28, 84, and 112, the lower boundaries of the 95% confidence intervals for the between-group differences (between each of the NmCV-5 groups and the MenACWY-D group) were above −10 percentage points. Similar results were observed with regard to the percentage of participants who had an increase of at least 4 times the baseline titer on days 28 and 112. These results suggest the noninferiority of NmCV-5 to MenACWY-D regarding these end points and are in line with the results observed with Menveo, which has also been shown to elicit noninferior or superior immune responses to those of MenACWY-D for all four serogroups included in these two vaccines.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22" id="body-ref-r22" href-manipulated="true">21,22</a></sup></div><div role="paragraph">At baseline, the percentage of participants with SBA titers of at least 128 was 15% or less for all five serogroups. This finding indicates a decrease in maternal antibodies as well as increasing susceptibility to meningococcal infections by 12 months of age.</div><div role="paragraph">Since there was no observed benefit of the adjuvanted formulation over the nonadjuvanted formulation, as well as no notable safety concerns, the nonadjuvanted NmCV-5 formulation was selected for further evaluation. Two phase 3 trials are ongoing to target mass immunization campaigns (in 2-to 29-year-old persons in Gambia and Mali; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03964012" target="_blank">NCT03964012</a>) and vaccination in travelers to high-risk regions (with a trial involving 18-to 85-year-old persons in India; <a href="http://clinicaltrials.gov/show/NCT04358731" target="_blank">NCT04358731</a>).</div><div role="paragraph">The results of this trial suggest that NmCV-5 has the potential to affect outbreaks of serotype A, C, W, Y, or X in the sub-Saharan African meningitis belt, a finding that is analogous to the success seen with MenAfriVac. Several studies have shown that expanding the coverage of a monovalent serogroup A to a multivalent vaccine would be cost-effective.<sup><a href="#core-r23" role="doc-biblioref" data-xml-rid="r23 r24 r25" id="body-ref-r25" href-manipulated="true">23-25</a></sup></div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by the <span class="named-content" data-type="funder">U.K. Foreign, Commonwealth, and Development Office</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank the trial participants and their parents, all the research staff at Centre pour le Développement des Vaccins du Mali (in Bamako), and all the members of the data and safety monitoring board (Drs. Doudou Diop, Brian Greenwood, Oomen John, Tatiana Keita, and Peter Smith).</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2013615_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2013615/suppl_file/nejmoa2013615_protocol.pdf" download="nejmoa2013615_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2013615_protocol.pdf" data-doi="10.1056/NEJMoa2013615">Download</a></li><li>12.88 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2013615_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2013615/suppl_file/nejmoa2013615_appendix.pdf" download="nejmoa2013615_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2013615_appendix.pdf" data-doi="10.1056/NEJMoa2013615">Download</a></li><li>885.43 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2013615_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2013615/suppl_file/nejmoa2013615_disclosures.pdf" download="nejmoa2013615_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2013615_disclosures.pdf" data-doi="10.1056/NEJMoa2013615">Download</a></li><li>387.72 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2013615_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2013615/suppl_file/nejmoa2013615_data-sharing.pdf" download="nejmoa2013615_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2013615_data-sharing.pdf" data-doi="10.1056/NEJMoa2013615">Download</a></li><li>69.35 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Meningococcal meningitis. World Health Organization, 2018 (<a href="https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis">https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Meningococcal+meningitis.+World+Health+Organization%2C+2018+%28https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fmeningococcal-meningitis%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] large epidemics every 7 to 14 years. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] epilepsy, and other neurologic disorders. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Meningococcal disease in countries of the African meningitis belt, 2012 — emerging needs and future perspectives. <em>Wkly Epidemiol Rec</em> 2013;88:129-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23544241/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+disease+in+countries+of+the+African+meningitis+belt%2C+2012+%E2%80%94+emerging+needs+and+future+perspectives.&amp;publication_year=2013&amp;journal=Wkly+Epidemiol+Rec&amp;pages=129-136&amp;pmid=23544241" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. <em>Vaccine</em> 2009;27:Suppl 2:B51-B63.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2009.04.063" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19477562/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000267956400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+epidemiology+of+meningococcal+disease.&amp;publication_year=2009&amp;journal=Vaccine&amp;pages=B51-B63&amp;doi=10.1016%2Fj.vaccine.2009.04.063&amp;pmid=19477562" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Meningococcal meningitis weekly reports: 2013–2017. World Health Organization (<a href="http://www.who.int/csr/disease/meningococcal/epidemiological/en/index.html">http://www.who.int/csr/disease/meningococcal/epidemiological/en/index.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Meningococcal+meningitis+weekly+reports%3A+2013%E2%80%932017.+World+Health+Organization+%28http%3A%2F%2Fwww.who.int%2Fcsr%2Fdisease%2Fmeningococcal%2Fepidemiological%2Fen%2Findex.html%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Epidemic meningitis control in countries of the African meningitis belt, 2016. <em>Wkly Epidemiol Rec</em> 2017;92:145-154.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28361528/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemic+meningitis+control+in+countries+of+the+African+meningitis+belt%2C+2016.&amp;publication_year=2017&amp;journal=Wkly+Epidemiol+Rec&amp;pages=145-154&amp;pmid=28361528" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS. Challenges and opportunities while developing a group A meningococcal conjugate vaccine within a product development partnership: a manufacturer’s perspective from the Serum Institute of India. <em>Clin Infect Dis</em> 2015;61:Suppl 5:S483-S488.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/civ500" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26553678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365162700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Challenges+and+opportunities+while+developing+a+group+A+meningococcal+conjugate+vaccine+within+a+product+development+partnership%3A+a+manufacturer%E2%80%99s+perspective+from+the+Serum+Institute+of+India.&amp;publication_year=2015&amp;journal=Clin+Infect+Dis&amp;pages=S483-S488&amp;doi=10.1093%2Fcid%2Fciv500&amp;pmid=26553678" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Stuart JM. Impact of serogroup A meningococcal conjugate vaccine for Africa. <em>Hum Vaccin Immunother</em> 2018;14:1116-1117.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/21645515.2017.1412022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29194010/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000433960500023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+serogroup+A+meningococcal+conjugate+vaccine+for+Africa.&amp;publication_year=2018&amp;journal=Hum+Vaccin+Immunother&amp;pages=1116-1117&amp;doi=10.1080%2F21645515.2017.1412022&amp;pmid=29194010" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. <em>Lancet Infect Dis</em> 2017;17:867-872.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(17)30301-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28545721/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405856500031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+MenAfriVac+in+nine+countries+of+the+African+meningitis+belt%2C+2010-15%3A+an+analysis+of+surveillance+data.&amp;publication_year=2017&amp;journal=Lancet+Infect+Dis&amp;pages=867-872&amp;doi=10.1016%2FS1473-3099%2817%2930301-8&amp;pmid=28545721" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. <em>Clin Infect Dis</em> 2015;61:Suppl 5:S410-S415.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/civ597" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26553668/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365162700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+meningitis+surveillance+in+the+African+meningitis+belt%2C+2004-2013.&amp;publication_year=2015&amp;journal=Clin+Infect+Dis&amp;pages=S410-S415&amp;doi=10.1093%2Fcid%2Fciv597&amp;pmid=26553668" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Nnadi C, Oladejo J, Yennan S, et al. Large outbreak of Neisseria meningitidis serogroup C — Nigeria, December 2016–June 2017. <em>MMWR Morb Mortal Wkly Rep</em> 2017;66:1352-1356.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm6649a3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29240724/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000418067200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Large+outbreak+of+Neisseria+meningitidis+serogroup+C+%E2%80%94+Nigeria%2C+December+2016%E2%80%93June+2017.&amp;publication_year=2017&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=1352-1356&amp;doi=10.15585%2Fmmwr.mm6649a3&amp;pmid=29240724" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Retchless AC, Congo-Ouédraogo M, Kambiré D, et al. Molecular characterization of invasive meningococcal isolates in Burkina Faso as the relative importance of serogroups X and W increases, 2008–2012. <em>BMC Infect Dis</em> 2018;18:37-37.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12879-018-3247-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30021533/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439147400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+characterization+of+invasive+meningococcal+isolates+in+Burkina+Faso+as+the+relative+importance+of+serogroups+X+and+W+increases%2C+2008%E2%80%932012.&amp;publication_year=2018&amp;journal=BMC+Infect+Dis&amp;pages=37-37&amp;doi=10.1186%2Fs12879-018-3247-x&amp;pmid=30021533" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Agnememel A, Hong E, Giorgini D, Nuñez-Samudio V, Deghmane A-E, Taha M-K. Neisseria meningitidis serogroup X in sub-Saharan Africa. <em>Emerg Infect Dis</em> 2016;22:698-702.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2204.150653" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26982628/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000372688500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neisseria+meningitidis+serogroup+X+in+sub-Saharan+Africa.&amp;publication_year=2016&amp;journal=Emerg+Infect+Dis&amp;pages=698-702&amp;doi=10.3201%2Feid2204.150653&amp;pmid=26982628" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence. <em>Hum Vaccin Immunother</em> 2016;12:1825-1837.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26900984/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382781100031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+quadrivalent+tetanus+toxoid+conjugate+vaccine+%28MenACWY-TT%2C+Nimenrix%29%3A+a+review+of+its+immunogenicity%2C+safety%2C+co-administration%2C+and+antibody+persistence.&amp;publication_year=2016&amp;journal=Hum+Vaccin+Immunother&amp;pages=1825-1837&amp;pmid=26900984" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. <em>Lancet Infect Dis</em> 2018;18:1088-1096.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(18)30400-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30120069/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445774200031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+pentavalent+meningococcal+conjugate+vaccine+containing+serogroups+A%2C+C%2C+Y%2C+W%2C+and+X+in+healthy+adults%3A+a+phase+1%2C+single-centre%2C+double-blind%2C+randomised%2C+controlled+study.&amp;publication_year=2018&amp;journal=Lancet+Infect+Dis&amp;pages=1088-1096&amp;doi=10.1016%2FS1473-3099%2818%2930400-6&amp;pmid=30120069" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Lucidarme J, Louth J, Townsend-Payne K, Borrow R. Meningococcal serogroup A, B, C, W, X, and Y serum bactericidal antibody assays. <em>Methods Mol Biol</em> 2019;1969:169-179.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/978-1-4939-9202-7_12" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30877677/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+serogroup+A%2C+B%2C+C%2C+W%2C+X%2C+and+Y+serum+bactericidal+antibody+assays.&amp;publication_year=2019&amp;journal=Methods+Mol+Biol&amp;pages=169-179&amp;doi=10.1007%2F978-1-4939-9202-7_12&amp;pmid=30877677" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Miettinen O, Nurminen M. Comparative analysis of two rates. <em>Stat Med</em> 1985;4:213-226.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.4780040211" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/4023479/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1985ALC2100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+analysis+of+two+rates.&amp;publication_year=1985&amp;journal=Stat+Med&amp;pages=213-226&amp;doi=10.1002%2Fsim.4780040211&amp;pmid=4023479" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Menactra. Swiftwater, PA: Sanofi Pasteur, 2018 (<a href="https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf">https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf</a>) (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Menactra.+Swiftwater%2C+PA%3A+Sanofi+Pasteur%2C+2018+%28https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FBiologicsBloodVaccines%2FVaccines%2FApprovedProducts%2FUCM131170.pdf%29+%28package+insert%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Nimenrix) do not contain any adjuvant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in children 9 through 23 months of age, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Nimenrix summary of product characteristics. European Medicines Agency, 2017 (<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002226/WC500127663.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002226/WC500127663.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Nimenrix+summary+of+product+characteristics.+European+Medicines+Agency%2C+2017+%28http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FEPAR_-Product_Information%2Fhuman%2F002226%2FWC500127663.pdf%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Nimenrix) do not contain any adjuvant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to tetanus toxoid, at a one-dose schedule. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">MENVEO. Research Triangle Park, NC: GlaxoSmithKline, 2020 (<a href="https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf">https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf</a>) (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=MENVEO.+Research+Triangle+Park%2C+NC%3A+GlaxoSmithKline%2C+2020+%28https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FBiologicsBloodVaccines%2FVaccines%2FApprovedProducts%2FUCM201349.pdf%29+%28package+insert%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Nimenrix) do not contain any adjuvant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to tetanus toxoid, at a one-dose schedule. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. <em>Vaccine</em> 2013;31:2852-2861.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2013.04.036" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23623866/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000320970600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emergence+of+serogroup+X+meningococcal+disease+in+Africa%3A+need+for+a+vaccine.&amp;publication_year=2013&amp;journal=Vaccine&amp;pages=2852-2861&amp;doi=10.1016%2Fj.vaccine.2013.04.036&amp;pmid=23623866" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Deeks ED. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults. <em>BioDrugs</em> 2010;24:287-297.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2165/11204790-000000000-00000" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20795751/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000281937200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+quadrivalent+%28serogroups+A%2C+C%2C+w135%2C+and+y%29+conjugate+vaccine+%28Menveo%29%3A+in+adolescents+and+adults.&amp;publication_year=2010&amp;journal=BioDrugs&amp;pages=287-297&amp;doi=10.2165%2F11204790-000000000-00000&amp;pmid=20795751" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. <em>Vaccine</em> 2010;28:7865-7872.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2010.09.092" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20943209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285667400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+safety+and+immunogenicity+of+an+investigational+and+a+licensed+quadrivalent+meningococcal+conjugate+vaccine+in+children+2-10+years+of+age.&amp;publication_year=2010&amp;journal=Vaccine&amp;pages=7865-7872&amp;doi=10.1016%2Fj.vaccine.2010.09.092&amp;pmid=20943209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Kuznik A, Iliyasu G, Lamorde M, et al. Cost-effectiveness of expanding childhood routine immunization against <i>Neisseria meningitidis</i> serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. <em>PLoS One</em> 2017;12(11):e0188595-e0188595.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0188595" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29190699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000416841900080" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cost-effectiveness+of+expanding+childhood+routine+immunization+against+Neisseria+meningitidis+serogroups+C%2C+W+and+Y+with+a+quadrivalent+conjugate+vaccine+in+the+African+meningitis+belt.&amp;publication_year=2017&amp;journal=PLoS+One&amp;pages=e0188595-e0188595&amp;doi=10.1371%2Fjournal.pone.0188595&amp;pmid=29190699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Yaesoubi R, Trotter C, Colijn C, et al. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: a transmission dynamic modeling study. <em>PLoS Med</em> 2018;15(1):e1002495-e1002495.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1002495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29364884/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423818400016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+cost-effectiveness+of+alternative+vaccination+strategies+for+polyvalent+meningococcal+vaccines+in+Burkina+Faso%3A+a+transmission+dynamic+modeling+study.&amp;publication_year=2018&amp;journal=PLoS+Med&amp;pages=e1002495-e1002495&amp;doi=10.1371%2Fjournal.pmed.1002495&amp;pmid=29364884" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Arifin SMN, Zimmer C, Trotter C, et al. Cost-effectiveness of alternative uses of polyvalent meningococcal vaccines in Niger: an agent-based transmission modeling study. <em>Med Decis Making</em> 2019;39:553-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0272989X19859899" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31268405/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000476280600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cost-effectiveness+of+alternative+uses+of+polyvalent+meningococcal+vaccines+in+Niger%3A+an+agent-based+transmission+modeling+study.&amp;publication_year=2019&amp;journal=Med+Decis+Making&amp;pages=553-567&amp;doi=10.1177%2F0272989X19859899&amp;pmid=31268405" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/384/22"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">384</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">22</span></span> • <span property="datePublished">June 3, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2115</span>-<span property="pageEnd">2123</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: June 2, 2021</div><div><b class="core-label">Published in issue</b>: June 3, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/bacterial-infections" alt="View article keyword Bacterial Infections" data-interactiontype="article_recirculation_click">Bacterial Infections</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/childhood-diseases" alt="View article keyword Childhood Diseases" data-interactiontype="article_recirculation_click">Childhood Diseases</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/global-health" alt="View article keyword Global Health" data-interactiontype="article_recirculation_click">Global Health</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/immunization" alt="View article keyword Immunization" data-interactiontype="article_recirculation_click">Immunization</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/infectious-disease-general" alt="View article keyword Infectious Disease General" data-interactiontype="article_recirculation_click">Infectious Disease General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/vaccines" alt="View article keyword Vaccines" data-interactiontype="article_recirculation_click">Vaccines</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Milagritos D.</span> <span property="familyName">Tapia</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Samba O.</span> <span property="familyName">Sow</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Abdi</span> <span property="familyName">Naficy</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fatoumata</span> <span property="familyName">Diallo</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Fadima C.</span> <span property="familyName">Haidara</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Amol</span> <span property="familyName">Chaudhari</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0001-9972-9755" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0001-9972-9755</a></span>, <span property="author" typeof="Person"><span property="givenName">Lionel</span> <span property="familyName">Martellet</span>, <span property="honorificSuffix">M.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Awa</span> <span property="familyName">Traore</span>, <span property="honorificSuffix">Pharm.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kelly</span> <span property="familyName">Townsend-Payne</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ray</span> <span property="familyName">Borrow</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nancy</span> <span property="familyName">Hosken</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Igor</span> <span property="familyName">Smolenov</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sambhaji S.</span> <span property="familyName">Pisal</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">F. Marc</span> <span property="familyName">LaForce</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rajeev M.</span> <span property="familyName">Dhere</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Dhananjay</span> <span property="familyName">Kapse</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yuxiao</span> <span property="familyName">Tang</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark R.</span> <span property="familyName">Alderson</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Prasad S.</span> <span property="familyName">Kulkarni</span>, <span property="honorificSuffix">M.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Centre pour le Développement des Vaccins du Mali, Bamako (M.D.T., S.O.S., F.D., F.C.H., A.T.); the Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore (M.D.T.); PATH, Seattle (A.N., L.M., N.H., I.S., Y.T., M.R.A.); the Serum Institute of India, Pune (A.C., S.S.P., F.M.L., R.M.D., D.K., P.S.K.); and the Vaccine Evaluation Unit, Public Health England, Manchester Royal Infirmary, Manchester, United Kingdom (K.T.-P., R.B.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Kulkarni at the Serum Institute of India, 212/2, Hadapsar, Pune 411028, India, or at <a href="mailto:drpsk@seruminstitute.com">drpsk@seruminstitute.com</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">24</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2013615" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="4d6466ae-47cc-1bc3-ed3b-067faa05f093"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156" style="display:inline-block;">
                <img alt="Article has an altmetric score of 90" src="https://badges.altmetric.com/?size=320&amp;score=90&amp;types=mattttfd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_4d6466ae-47cc-1bc3-ed3b-067faa05f093" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156&amp;tab=news">
          Picked up by <b>8</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156&amp;tab=policy-documents">
          Referenced in <b>3</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156&amp;tab=twitter">
          Posted by <b>21</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=106914156&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>73</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d683a4e0d7a511-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2013615"> <input type="hidden" name="downloadFileName" value="csp_384_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2013615%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-22%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="24" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Sushil Patni, </li><li class="list-inline-item cited-by__entry__author">Reena Verma, </li><li class="list-inline-item cited-by__entry__author">Mahavir Desarda, </li><li class="list-inline-item cited-by__entry__author">Sandip Naikwade, </li><li class="list-inline-item cited-by__entry__author">Hemant Deorukhakar, </li><li class="list-inline-item cited-by__entry__author">Rajeev Dhere, </li><li class="list-inline-item cited-by__entry__author">Asha Mallya, </li></ul><span class="cited-by__entry__title">Development of multiplexed flow based assay for simultaneous identification and estimation of meningococcal capsular polysaccharide serogroups A, C, W, Y and X for conjugate vaccine manufacturing, </span><span class="cited-by__entry__series-title">Journal of Immunological Methods, </span><span class="cited-by__entry__page-range">(113895), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jim.2025.113895" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jim.2025.113895</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jim.2025.113895" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Nicholas Aderinto, </li><li class="list-inline-item cited-by__entry__author">Gbolahan Olatunji, </li><li class="list-inline-item cited-by__entry__author">Emmanuel Kokori, </li><li class="list-inline-item cited-by__entry__author">Ikponmwosa Jude Ogieuhi, </li><li class="list-inline-item cited-by__entry__author">Adedoyin Esther Alao, </li><li class="list-inline-item cited-by__entry__author">Oluwafemi Isaiah Ajimotokan, </li><li class="list-inline-item cited-by__entry__author">Okam Onyinyechi Victoria, </li><li class="list-inline-item cited-by__entry__author">Oluwatosin Ayokunle Akinruli, </li><li class="list-inline-item cited-by__entry__author">Matthew Tolulope Olawoyin, </li></ul><span class="cited-by__entry__title">Nigeria introduces the world’s first Men5 CV meningitis vaccine, </span><span class="cited-by__entry__series-title">Discover Public Health, </span><span class="cited-by__entry__volume"><strong>22</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1186/s12982-025-00592-9" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1186/s12982-025-00592-9</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1186/s12982-025-00592-9" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ergin Ciftci, </li><li class="list-inline-item cited-by__entry__author">Duygu Ocal, </li><li class="list-inline-item cited-by__entry__author">Ayper Somer, </li><li class="list-inline-item cited-by__entry__author">Hasan Tezer, </li><li class="list-inline-item cited-by__entry__author">Dilek Yilmaz, </li><li class="list-inline-item cited-by__entry__author">Sirac Bozkurt, </li><li class="list-inline-item cited-by__entry__author">Oldac Uras Dursun, </li><li class="list-inline-item cited-by__entry__author">Şeyhmus Merter, </li><li class="list-inline-item cited-by__entry__author">Ener Cagri Dinleyici, </li></ul><span class="cited-by__entry__title">Current methods in the diagnosis of invasive meningococcal disease, </span><span class="cited-by__entry__series-title">Frontiers in Pediatrics, </span><span class="cited-by__entry__volume"><strong>13</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fped.2025.1511086" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fped.2025.1511086</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fped.2025.1511086" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Prasad S Kulkarni, </li><li class="list-inline-item cited-by__entry__author">Anand Kawade, </li><li class="list-inline-item cited-by__entry__author">Sunil Kohli, </li><li class="list-inline-item cited-by__entry__author">Renuka Munshi, </li><li class="list-inline-item cited-by__entry__author">Chetna Maliye, </li><li class="list-inline-item cited-by__entry__author">Nithya J Gogtay, </li><li class="list-inline-item cited-by__entry__author">Ravish H S, </li><li class="list-inline-item cited-by__entry__author">Kiranjit Singh, </li><li class="list-inline-item cited-by__entry__author">K Vengadakrishnan, </li><li class="list-inline-item cited-by__entry__author">Sandeep Kumar Panigrahi, </li><li class="list-inline-item cited-by__entry__author">Jyotiranjan Sahoo, </li><li class="list-inline-item cited-by__entry__author">Ashish Bavdekar, </li><li class="list-inline-item cited-by__entry__author">B S Garg, </li><li class="list-inline-item cited-by__entry__author">Abhishek Raut, </li><li class="list-inline-item cited-by__entry__author">Jeffrey P Raj, </li><li class="list-inline-item cited-by__entry__author">Unnati Saxena, </li><li class="list-inline-item cited-by__entry__author">Vijaya L Chaudhari, </li><li class="list-inline-item cited-by__entry__author">Rakesh Patil, </li><li class="list-inline-item cited-by__entry__author">Epari Venkatarao, </li><li class="list-inline-item cited-by__entry__author">Nitu Kumari, </li><li class="list-inline-item cited-by__entry__author">Jithin Surendran, </li><li class="list-inline-item cited-by__entry__author">Varsha Parulekar, </li><li class="list-inline-item cited-by__entry__author">Luc Gagnon, </li><li class="list-inline-item cited-by__entry__author">Tania Gensale, </li><li class="list-inline-item cited-by__entry__author">Abhijeet Dharmadhikari, </li><li class="list-inline-item cited-by__entry__author">Sunil Gairola, </li><li class="list-inline-item cited-by__entry__author">Sameer Kale, </li><li class="list-inline-item cited-by__entry__author">Sambhaji S Pisal, </li><li class="list-inline-item cited-by__entry__author">Rajeev M Dhere, </li><li class="list-inline-item cited-by__entry__author">Asha Mallya, </li><li class="list-inline-item cited-by__entry__author">Cyrus S Poonawalla, </li><li class="list-inline-item cited-by__entry__author">Dhananjay Kapse, </li></ul><span class="cited-by__entry__title">Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine versus a quadrivalent meningococcal conjugate vaccine in adults in India: an observer-blind, randomised, active-controlled, phase 2/3 study, </span><span class="cited-by__entry__series-title">The Lancet Infectious Diseases, </span><span class="cited-by__entry__volume"><strong>25</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(399-410), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S1473-3099(24)00576-0" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S1473-3099(24)00576-0</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S1473-3099(24)00576-0" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Fatoumata Diallo, </li><li class="list-inline-item cited-by__entry__author">Fadima C Haidara, </li><li class="list-inline-item cited-by__entry__author">Milagritos D Tapia, </li><li class="list-inline-item cited-by__entry__author">Clara P Dominguez Islas, </li><li class="list-inline-item cited-by__entry__author">Mark R Alderson, </li><li class="list-inline-item cited-by__entry__author">William P Hausdorff, </li><li class="list-inline-item cited-by__entry__author">Lionel Martellet, </li><li class="list-inline-item cited-by__entry__author">Nancy Hosken, </li><li class="list-inline-item cited-by__entry__author">Dhananjay Kapse, </li><li class="list-inline-item cited-by__entry__author">Prasad S Kulkarni, </li><li class="list-inline-item cited-by__entry__author">Kelly Townsend-Payne, </li><li class="list-inline-item cited-by__entry__author">Francesca Vanni, </li><li class="list-inline-item cited-by__entry__author">Christine M Posavad, </li><li class="list-inline-item cited-by__entry__author">Samba O Sow, </li><li class="list-inline-item cited-by__entry__author">Karen L Kotloff, </li><li class="list-inline-item cited-by__entry__author">Wilbur H Chen, </li><li class="list-inline-item cited-by__entry__author">Fatoumata Diallo, </li><li class="list-inline-item cited-by__entry__author">Fadima C. Haidara, </li><li class="list-inline-item cited-by__entry__author">Milagritos D. Tapia, </li><li class="list-inline-item cited-by__entry__author">Souleymane Diakité, </li><li class="list-inline-item cited-by__entry__author">Youssouf Traoré, </li><li class="list-inline-item cited-by__entry__author">Awa Traoré, </li><li class="list-inline-item cited-by__entry__author">Mamoudou Kodio, </li><li class="list-inline-item cited-by__entry__author">Clara P. Dominguez Islas, </li><li class="list-inline-item cited-by__entry__author">Fleesie A. Hubbard, </li><li class="list-inline-item cited-by__entry__author">William P. Hausdorff, </li><li class="list-inline-item cited-by__entry__author">Lionel Martellet, </li><li class="list-inline-item cited-by__entry__author">Nancy Hosken, </li><li class="list-inline-item cited-by__entry__author">Mark R. Alderson, </li><li class="list-inline-item cited-by__entry__author">Dhananjay Kapse, </li><li class="list-inline-item cited-by__entry__author">Prasad S. Kulkarni, </li><li class="list-inline-item cited-by__entry__author">Kelly Townsend-Payne, </li><li class="list-inline-item cited-by__entry__author">Francesca Vanni, </li><li class="list-inline-item cited-by__entry__author">Monica M. Farley, </li><li class="list-inline-item cited-by__entry__author">Brett S. Hanscom, </li><li class="list-inline-item cited-by__entry__author">Clifton W. Kelly, </li><li class="list-inline-item cited-by__entry__author">Christine M. Posavad, </li><li class="list-inline-item cited-by__entry__author">Samba O. Sow, </li><li class="list-inline-item cited-by__entry__author">Karen L. Kotloff, </li><li class="list-inline-item cited-by__entry__author">Wilbur H. Chen, </li></ul><span class="cited-by__entry__title">Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial, </span><span class="cited-by__entry__series-title">The Lancet, </span><span class="cited-by__entry__volume"><strong>405</strong>, </span><span class="cited-by__entry__issue">10484, </span><span class="cited-by__entry__page-range">(1069-1080), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/S0140-6736(25)00046-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/S0140-6736(25)00046-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/S0140-6736(25)00046-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yuxiang Zhang, </li></ul><span class="cited-by__entry__title">Impact of the Pentavalent Meningococcal Conjugate Vaccine(NmCV-5) Targeting Serogroups A,C,Y,W, and X on the Sub-Saharan Africa Region, </span><span class="cited-by__entry__series-title">Transactions on Materials, Biotechnology and Life Sciences, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__page-range">(420-426), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.62051/gmvqsc77" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.62051/gmvqsc77</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.62051/gmvqsc77" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ray Borrow, </li><li class="list-inline-item cited-by__entry__author">Helen Campbell, </li><li class="list-inline-item cited-by__entry__author">Dominique A. Caugant, </li><li class="list-inline-item cited-by__entry__author">Abdessalam Cherkaoui, </li><li class="list-inline-item cited-by__entry__author">Heike Claus, </li><li class="list-inline-item cited-by__entry__author">Ala-Eddine Deghmane, </li><li class="list-inline-item cited-by__entry__author">Ener Cagri Dinleyici, </li><li class="list-inline-item cited-by__entry__author">Lee H. Harrison, </li><li class="list-inline-item cited-by__entry__author">William P. Hausdorff, </li><li class="list-inline-item cited-by__entry__author">Paula Bajanca-Lavado, </li><li class="list-inline-item cited-by__entry__author">Corinne Levy, </li><li class="list-inline-item cited-by__entry__author">Wesley Mattheus, </li><li class="list-inline-item cited-by__entry__author">Claudia Mikula-Pratschke, </li><li class="list-inline-item cited-by__entry__author">Paula Mölling, </li><li class="list-inline-item cited-by__entry__author">Marco AP Sáfadi, </li><li class="list-inline-item cited-by__entry__author">Vinny Smith, </li><li class="list-inline-item cited-by__entry__author">Nina M. van Sorge, </li><li class="list-inline-item cited-by__entry__author">Paola Stefanelli, </li><li class="list-inline-item cited-by__entry__author">Muhamed-Kheir Taha, </li><li class="list-inline-item cited-by__entry__author">Maija Toropainen, </li><li class="list-inline-item cited-by__entry__author">Georgina Tzanakaki, </li><li class="list-inline-item cited-by__entry__author">Julio Vázquez, </li></ul><span class="cited-by__entry__title">Global Meningococcal Initiative: Insights on antibiotic resistance, control strategies and advocacy efforts in Western Europe, </span><span class="cited-by__entry__series-title">Journal of Infection, </span><span class="cited-by__entry__volume"><strong>89</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(106335), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1016/j.jinf.2024.106335" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jinf.2024.106335</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jinf.2024.106335" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yoonjin Kim, </li><li class="list-inline-item cited-by__entry__author">Sungyeun Bae, </li><li class="list-inline-item cited-by__entry__author">Kyung-Sang Yu, </li><li class="list-inline-item cited-by__entry__author">SeungHwan Lee, </li><li class="list-inline-item cited-by__entry__author">Chankyu Lee, </li><li class="list-inline-item cited-by__entry__author">Jinil Kim, </li><li class="list-inline-item cited-by__entry__author">Howard Her, </li><li class="list-inline-item cited-by__entry__author">Jaeseong Oh, </li></ul><span class="cited-by__entry__title">A randomized study to evaluate the safety and immunogenicity of a pentavalent meningococcal vaccine, </span><span class="cited-by__entry__series-title">npj Vaccines, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1038/s41541-024-00935-8" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41541-024-00935-8</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41541-024-00935-8" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Markus Knuf, </li></ul><span class="cited-by__entry__title">MeningokokkenimpfungMeningococcal vaccination, </span><span class="cited-by__entry__series-title">Monatsschrift Kinderheilkunde, </span><span class="cited-by__entry__volume"><strong>172</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(386-395), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1007/s00112-024-01951-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s00112-024-01951-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s00112-024-01951-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ray Borrow, </li><li class="list-inline-item cited-by__entry__author">Jamie Findlow, </li></ul><span class="cited-by__entry__title">The important lessons lurking in the history of meningococcal epidemiology, </span><span class="cited-by__entry__series-title">Expert Review of Vaccines, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">1, </span><span class="cited-by__entry__page-range">(445-462), </span><span class="cited-by__entry__pub-date">(2024).</span><a href="https://doi.org/10.1080/14760584.2024.2329618" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/14760584.2024.2329618</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/14760584.2024.2329618" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2013615%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.384.issue-22%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2013615" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2013615" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2013615.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2013615_f1.jpg"><img src="/cms/10.1056/NEJMoa2013615/asset/d0e5fe79-1afa-427e-8eb0-f919689733a0/assets/images/large/nejmoa2013615_f1.jpg" height="1140" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Geometric Mean Titers of Serum Bactericidal Antibody, According to Meningococcal Serogroup (Per-Protocol Population).</div><div class="notes"><div role="doc-footnote">Shown are the geometric mean titers and 95% confidence intervals (𝙸 bars) of the serum bactericidal antibody with baby rabbit complement that were observed in participants who received nonadjuvanted NmCV-5, adjuvanted NmCV-5, or MenACWY-D at baseline (day 0), at 28 days and 84 days after receipt of the first dose (days 28 and 84), and at 28 days after receipt of the second dose (day 112). The per-protocol population included all the participants who correctly received their assigned trial vaccine with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the trial vaccines and who provided, at least at one time point after vaccination, a serum sample that could be evaluated.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2013615_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2013615/asset/b1d0ba86-bc2e-4fa6-9f2a-d19f2fd0ecf2/assets/images/large/nejmoa2013615_t1.jpg" height="2056" width="1712" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Day and Serogroup</th><th class="txxx-borders" colspan="2"><span>Nonadjuvanted NmCV-5<br>(N=144)</span></th><th class="txxx-borders" colspan="2"><span>Adjuvanted NmCV-5<br>(N=144)</span></th><th class="txxr-borders" colspan="2"><span>MenACWY-D<br>(N=72)</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxr-borders">% (95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 0</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">16</td><td class="xxxx-borders">11 (6 to 17)</td><td class="xxxx-borders">18</td><td class="xxxx-borders">12 (8 to 19)</td><td class="xxxx-borders">10</td><td class="xxxr-borders">14 (7 to 24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">1 (&lt;1 to 5)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0 (0 to 3)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0 (0 to 5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">8</td><td class="xxxx-borders">6 (2 to 11)</td><td class="xxxx-borders">5</td><td class="xxxx-borders">3 (1 to 8)</td><td class="xxxx-borders">2</td><td class="xxxr-borders">3 (&lt;1 to 10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">16</td><td class="xxxx-borders shading">11 (6 to 17)</td><td class="xxxx-borders shading">21</td><td class="xxxx-borders shading">15 (9 to 21)</td><td class="xxxx-borders shading">10</td><td class="xxxr-borders shading">14 (7 to 24)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">15</td><td class="xxxx-borders">10 (6 to 17)</td><td class="xxxx-borders">12</td><td class="xxxx-borders">8 (4 to 14)</td><td class="xxxx-borders">6</td><td class="xxxr-borders">8 (3 to 17)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 28</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">140</td><td class="xxxx-borders shading">97 (93 to 99)</td><td class="xxxx-borders shading">39</td><td class="xxxr-borders shading">54 (42 to 66)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">142</td><td class="xxxx-borders">99 (95 to &gt;99)</td><td class="xxxx-borders">141</td><td class="xxxx-borders">98 (94 to &gt;99)</td><td class="xxxx-borders">65</td><td class="xxxr-borders">90 (81 to 96)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">140</td><td class="xxxx-borders shading">97 (93 to 99)</td><td class="xxxx-borders shading">143</td><td class="xxxx-borders shading">99 (96 to &gt;99)</td><td class="xxxx-borders shading">64</td><td class="xxxr-borders shading">89 (79 to 95)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">15</td><td class="xxxr-borders">21 (12 to 32)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 84</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">133</td><td class="xxxx-borders shading">92 (87 to 96)</td><td class="xxxx-borders shading">131</td><td class="xxxx-borders shading">91 (85 to 95)</td><td class="xxxx-borders shading">26</td><td class="xxxr-borders shading">36 (25 to 48)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">137</td><td class="xxxx-borders">95 (90 to 98)</td><td class="xxxx-borders">139</td><td class="xxxx-borders">97 (92 to 99)</td><td class="xxxx-borders">57</td><td class="xxxr-borders">79 (68 to 88)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">138</td><td class="xxxx-borders shading">96 (91 to 98)</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">98 (94 to &gt;99)</td><td class="xxxx-borders shading">60</td><td class="xxxr-borders shading">83 (73 to 91)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">14</td><td class="xxxr-borders">19 (11 to 30)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 112</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">72</td><td class="xxxr-borders">100 (95 to 100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">68</td><td class="xxxr-borders shading">94 (86 to 98)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">69</td><td class="xxxr-borders">96 (88 to 99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">66</td><td class="xxxr-borders shading">92 (83 to 97)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">X</td><td class="xbxx-borders">143</td><td class="xbxx-borders">99 (96 to &gt;99)</td><td class="xbxx-borders">144</td><td class="xbxx-borders">100 (97 to 100)</td><td class="xbxx-borders">22</td><td class="xbxr-borders">31 (20 to 43)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">The titers of serum bactericidal antibody with rabbit complement were assessed at baseline (day 0), at 28 days and 84 days after receipt of the first dose (days 28 and 84), and 28 days after receipt of the second dose (day 112). The per-protocol population included all the participants who correctly received their assigned trial vaccine with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment and who provided, at least at one time point after vaccination, a serum sample that could be evaluated. For percentage calculations, the denominator is the number of participants with nonmissing values at baseline and postvaccination visits. Data were missing at day 0 for serogroup C in 1 participant in the nonadjuvanted NmCV-5 group and for serogroup W in 1 participant in each NmCV-5 group. CI denotes confidence interval.</div></div></div></figcaption></a><figcaption><div class="caption">Participants with Serum Bactericidal Antibody Titers of at Least 128 at Days 0, 28, 84, and 112 (Per-Protocol Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2013615/asset/c5842390-5bbd-4dfb-9601-8fe20b6a3ea7/assets/images/large/nejmoa2013615_t2.jpg" height="1289" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Trial Day and Serogroup</th><th class="txxx-borders" colspan="2"><span>Nonadjuvanted NmCV-5<br>(N=144)</span></th><th class="txxx-borders" colspan="2"><span>Adjuvanted NmCV-5<br>(N=144)</span></th><th class="txxr-borders" colspan="2"><span>MenACWY-D<br>(N=72)</span></th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxx-borders">% (95% CI)</th><th class="xxxx-borders">no.</th><th class="xxxr-borders">% (95% CI)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 28</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">70</td><td class="xxxr-borders">97 (90 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">141</td><td class="xxxx-borders shading">98 (94 to &gt;99)</td><td class="xxxx-borders shading">50</td><td class="xxxr-borders shading">69 (57 to 80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">140</td><td class="xxxx-borders">98 (94 to &gt;99)</td><td class="xxxx-borders">140</td><td class="xxxx-borders">98 (94 to &gt;99)</td><td class="xxxx-borders">65</td><td class="xxxr-borders">90 (81 to 96)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">140</td><td class="xxxx-borders shading">97 (93 to 99)</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">63</td><td class="xxxr-borders shading">88 (78 to 94)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">X</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">142</td><td class="xxxx-borders">99 (95 to &gt;99)</td><td class="xxxx-borders">12</td><td class="xxxr-borders">17 (9 to 27)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Day 112</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">A</td><td class="xxxx-borders">143</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">144</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">C</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (96 to &gt;99)</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">72</td><td class="xxxr-borders shading">100 (95 to 100)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">W</td><td class="xxxx-borders">142</td><td class="xxxx-borders">99 (96 to &gt;99)</td><td class="xxxx-borders">143</td><td class="xxxx-borders">100 (97 to 100)</td><td class="xxxx-borders">71</td><td class="xxxr-borders">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Y</td><td class="xxxx-borders shading">144</td><td class="xxxx-borders shading">100 (97 to 100)</td><td class="xxxx-borders shading">142</td><td class="xxxx-borders shading">99 (95 to &gt;99)</td><td class="xxxx-borders shading">71</td><td class="xxxr-borders shading">99 (92 to &gt;99)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">X</td><td class="xbxx-borders">143</td><td class="xbxx-borders">99 (96 to &gt;99)</td><td class="xbxx-borders">143</td><td class="xbxx-borders">99 (96 to &gt;99)</td><td class="xbxx-borders">19</td><td class="xbxr-borders">26 (17 to 38)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">A serum bactericidal antibody titer of at least 4 times the baseline value was defined as follows: a postvaccination titer of at least 32 in participants with a prevaccination titer of less than 8, and a postvaccination titer of at least 4 times the prevaccination titer in participants with a prevaccination titer of 8 or higher. For percentage calculations, the denominator is the number of participants with nonmissing values at baseline and postvaccination visits. Data were missing at days 28 and 112 for serogroup C in 1 participant in the nonadjuvanted NmCV-5 group and for serogroup W in 1 participant in each NmCV-5 group.</div></div></div></figcaption></a><figcaption><div class="caption">Participants with an Increase in Serum Bactericidal Antibody Titers of at Least 4 Times the Baseline Value on Days 28 and 112 (Per-Protocol Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2013615_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2013615</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Meningococcal meningitis. World Health Organization, 2018 (<a href="https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis">https://www.who.int/news-room/fact-sheets/detail/meningococcal-meningitis</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r1-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Meningococcal+meningitis.+World+Health+Organization%2C+2018+%28https%3A%2F%2Fwww.who.int%2Fnews-room%2Ffact-sheets%2Fdetail%2Fmeningococcal-meningitis%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r1-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] large epidemics every 7 to 14 years. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r1-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] epilepsy, and other neurologic disorders. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Meningococcal disease in countries of the African meningitis belt, 2012 — emerging needs and future perspectives. <em>Wkly Epidemiol Rec</em> 2013;88:129-136.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23544241/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+disease+in+countries+of+the+African+meningitis+belt%2C+2012+%E2%80%94+emerging+needs+and+future+perspectives.&amp;publication_year=2013&amp;journal=Wkly+Epidemiol+Rec&amp;pages=129-136&amp;pmid=23544241" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. <em>Vaccine</em> 2009;27:Suppl 2:B51-B63.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2009.04.063" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19477562/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000267956400007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+epidemiology+of+meningococcal+disease.&amp;publication_year=2009&amp;journal=Vaccine&amp;pages=B51-B63&amp;doi=10.1016%2Fj.vaccine.2009.04.063&amp;pmid=19477562" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Meningococcal meningitis weekly reports: 2013–2017. World Health Organization (<a href="http://www.who.int/csr/disease/meningococcal/epidemiological/en/index.html">http://www.who.int/csr/disease/meningococcal/epidemiological/en/index.html</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Meningococcal+meningitis+weekly+reports%3A+2013%E2%80%932017.+World+Health+Organization+%28http%3A%2F%2Fwww.who.int%2Fcsr%2Fdisease%2Fmeningococcal%2Fepidemiological%2Fen%2Findex.html%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Epidemic meningitis control in countries of the African meningitis belt, 2016. <em>Wkly Epidemiol Rec</em> 2017;92:145-154.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28361528/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Epidemic+meningitis+control+in+countries+of+the+African+meningitis+belt%2C+2016.&amp;publication_year=2017&amp;journal=Wkly+Epidemiol+Rec&amp;pages=145-154&amp;pmid=28361528" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS. Challenges and opportunities while developing a group A meningococcal conjugate vaccine within a product development partnership: a manufacturer’s perspective from the Serum Institute of India. <em>Clin Infect Dis</em> 2015;61:Suppl 5:S483-S488.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/civ500" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26553678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365162700016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Challenges+and+opportunities+while+developing+a+group+A+meningococcal+conjugate+vaccine+within+a+product+development+partnership%3A+a+manufacturer%E2%80%99s+perspective+from+the+Serum+Institute+of+India.&amp;publication_year=2015&amp;journal=Clin+Infect+Dis&amp;pages=S483-S488&amp;doi=10.1093%2Fcid%2Fciv500&amp;pmid=26553678" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Stuart JM. Impact of serogroup A meningococcal conjugate vaccine for Africa. <em>Hum Vaccin Immunother</em> 2018;14:1116-1117.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1080/21645515.2017.1412022" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29194010/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000433960500023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+serogroup+A+meningococcal+conjugate+vaccine+for+Africa.&amp;publication_year=2018&amp;journal=Hum+Vaccin+Immunother&amp;pages=1116-1117&amp;doi=10.1080%2F21645515.2017.1412022&amp;pmid=29194010" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Trotter CL, Lingani C, Fernandez K, et al. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data. <em>Lancet Infect Dis</em> 2017;17:867-872.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r8"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(17)30301-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28545721/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000405856500031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Impact+of+MenAfriVac+in+nine+countries+of+the+African+meningitis+belt%2C+2010-15%3A+an+analysis+of+surveillance+data.&amp;publication_year=2017&amp;journal=Lancet+Infect+Dis&amp;pages=867-872&amp;doi=10.1016%2FS1473-3099%2817%2930301-8&amp;pmid=28545721" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. <em>Clin Infect Dis</em> 2015;61:Suppl 5:S410-S415.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/cid/civ597" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26553668/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000365162700006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+meningitis+surveillance+in+the+African+meningitis+belt%2C+2004-2013.&amp;publication_year=2015&amp;journal=Clin+Infect+Dis&amp;pages=S410-S415&amp;doi=10.1093%2Fcid%2Fciv597&amp;pmid=26553668" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Nnadi C, Oladejo J, Yennan S, et al. Large outbreak of Neisseria meningitidis serogroup C — Nigeria, December 2016–June 2017. <em>MMWR Morb Mortal Wkly Rep</em> 2017;66:1352-1356.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.15585/mmwr.mm6649a3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29240724/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000418067200003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Large+outbreak+of+Neisseria+meningitidis+serogroup+C+%E2%80%94+Nigeria%2C+December+2016%E2%80%93June+2017.&amp;publication_year=2017&amp;journal=MMWR+Morb+Mortal+Wkly+Rep&amp;pages=1352-1356&amp;doi=10.15585%2Fmmwr.mm6649a3&amp;pmid=29240724" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Retchless AC, Congo-Ouédraogo M, Kambiré D, et al. Molecular characterization of invasive meningococcal isolates in Burkina Faso as the relative importance of serogroups X and W increases, 2008–2012. <em>BMC Infect Dis</em> 2018;18:37-37.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s12879-018-3247-x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30021533/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000439147400002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Molecular+characterization+of+invasive+meningococcal+isolates+in+Burkina+Faso+as+the+relative+importance+of+serogroups+X+and+W+increases%2C+2008%E2%80%932012.&amp;publication_year=2018&amp;journal=BMC+Infect+Dis&amp;pages=37-37&amp;doi=10.1186%2Fs12879-018-3247-x&amp;pmid=30021533" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Agnememel A, Hong E, Giorgini D, Nuñez-Samudio V, Deghmane A-E, Taha M-K. Neisseria meningitidis serogroup X in sub-Saharan Africa. <em>Emerg Infect Dis</em> 2016;22:698-702.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.3201/eid2204.150653" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26982628/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000372688500017" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Neisseria+meningitidis+serogroup+X+in+sub-Saharan+Africa.&amp;publication_year=2016&amp;journal=Emerg+Infect+Dis&amp;pages=698-702&amp;doi=10.3201%2Feid2204.150653&amp;pmid=26982628" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Assaf-Casals A, Dbaibo G. Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence. <em>Hum Vaccin Immunother</em> 2016;12:1825-1837.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r13"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26900984/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000382781100031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+quadrivalent+tetanus+toxoid+conjugate+vaccine+%28MenACWY-TT%2C+Nimenrix%29%3A+a+review+of+its+immunogenicity%2C+safety%2C+co-administration%2C+and+antibody+persistence.&amp;publication_year=2016&amp;journal=Hum+Vaccin+Immunother&amp;pages=1825-1837&amp;pmid=26900984" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Chen WH, Neuzil KM, Boyce CR, et al. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. <em>Lancet Infect Dis</em> 2018;18:1088-1096.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1473-3099(18)30400-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30120069/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000445774200031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Safety+and+immunogenicity+of+a+pentavalent+meningococcal+conjugate+vaccine+containing+serogroups+A%2C+C%2C+Y%2C+W%2C+and+X+in+healthy+adults%3A+a+phase+1%2C+single-centre%2C+double-blind%2C+randomised%2C+controlled+study.&amp;publication_year=2018&amp;journal=Lancet+Infect+Dis&amp;pages=1088-1096&amp;doi=10.1016%2FS1473-3099%2818%2930400-6&amp;pmid=30120069" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Lucidarme J, Louth J, Townsend-Payne K, Borrow R. Meningococcal serogroup A, B, C, W, X, and Y serum bactericidal antibody assays. <em>Methods Mol Biol</em> 2019;1969:169-179.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r15"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1007/978-1-4939-9202-7_12" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30877677/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+serogroup+A%2C+B%2C+C%2C+W%2C+X%2C+and+Y+serum+bactericidal+antibody+assays.&amp;publication_year=2019&amp;journal=Methods+Mol+Biol&amp;pages=169-179&amp;doi=10.1007%2F978-1-4939-9202-7_12&amp;pmid=30877677" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Miettinen O, Nurminen M. Comparative analysis of two rates. <em>Stat Med</em> 1985;4:213-226.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.4780040211" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/4023479/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=A1985ALC2100010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparative+analysis+of+two+rates.&amp;publication_year=1985&amp;journal=Stat+Med&amp;pages=213-226&amp;doi=10.1002%2Fsim.4780040211&amp;pmid=4023479" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Menactra. Swiftwater, PA: Sanofi Pasteur, 2018 (<a href="https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf">https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf</a>) (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Menactra.+Swiftwater%2C+PA%3A+Sanofi+Pasteur%2C+2018+%28https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FBiologicsBloodVaccines%2FVaccines%2FApprovedProducts%2FUCM131170.pdf%29+%28package+insert%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Nimenrix) do not contain any adjuvant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in children 9 through 23 months of age, </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Nimenrix summary of product characteristics. European Medicines Agency, 2017 (<a href="http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002226/WC500127663.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-Product_Information/human/002226/WC500127663.pdf</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Nimenrix+summary+of+product+characteristics.+European+Medicines+Agency%2C+2017+%28http%3A%2F%2Fwww.ema.europa.eu%2Fdocs%2Fen_GB%2Fdocument_library%2FEPAR_-Product_Information%2Fhuman%2F002226%2FWC500127663.pdf%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Nimenrix) do not contain any adjuvant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to tetanus toxoid, at a one-dose schedule. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">MENVEO. Research Triangle Park, NC: GlaxoSmithKline, 2020 (<a href="https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf">https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM201349.pdf</a>) (package insert).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=MENVEO.+Research+Triangle+Park%2C+NC%3A+GlaxoSmithKline%2C+2020+%28https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FBiologicsBloodVaccines%2FVaccines%2FApprovedProducts%2FUCM201349.pdf%29+%28package+insert%29." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] and Nimenrix) do not contain any adjuvant. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r19-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to tetanus toxoid, at a one-dose schedule. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Xie O, Pollard AJ, Mueller JE, Norheim G. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. <em>Vaccine</em> 2013;31:2852-2861.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r20"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2013.04.036" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23623866/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000320970600002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Emergence+of+serogroup+X+meningococcal+disease+in+Africa%3A+need+for+a+vaccine.&amp;publication_year=2013&amp;journal=Vaccine&amp;pages=2852-2861&amp;doi=10.1016%2Fj.vaccine.2013.04.036&amp;pmid=23623866" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Deeks ED. Meningococcal quadrivalent (serogroups A, C, w135, and y) conjugate vaccine (Menveo): in adolescents and adults. <em>BioDrugs</em> 2010;24:287-297.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.2165/11204790-000000000-00000" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20795751/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000281937200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Meningococcal+quadrivalent+%28serogroups+A%2C+C%2C+w135%2C+and+y%29+conjugate+vaccine+%28Menveo%29%3A+in+adolescents+and+adults.&amp;publication_year=2010&amp;journal=BioDrugs&amp;pages=287-297&amp;doi=10.2165%2F11204790-000000000-00000&amp;pmid=20795751" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Halperin SA, Gupta A, Jeanfreau R, et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. <em>Vaccine</em> 2010;28:7865-7872.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r22"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.vaccine.2010.09.092" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20943209/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000285667400006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Comparison+of+the+safety+and+immunogenicity+of+an+investigational+and+a+licensed+quadrivalent+meningococcal+conjugate+vaccine+in+children+2-10+years+of+age.&amp;publication_year=2010&amp;journal=Vaccine&amp;pages=7865-7872&amp;doi=10.1016%2Fj.vaccine.2010.09.092&amp;pmid=20943209" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Kuznik A, Iliyasu G, Lamorde M, et al. Cost-effectiveness of expanding childhood routine immunization against <i>Neisseria meningitidis</i> serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt. <em>PLoS One</em> 2017;12(11):e0188595-e0188595.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pone.0188595" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29190699/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000416841900080" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cost-effectiveness+of+expanding+childhood+routine+immunization+against+Neisseria+meningitidis+serogroups+C%2C+W+and+Y+with+a+quadrivalent+conjugate+vaccine+in+the+African+meningitis+belt.&amp;publication_year=2017&amp;journal=PLoS+One&amp;pages=e0188595-e0188595&amp;doi=10.1371%2Fjournal.pone.0188595&amp;pmid=29190699" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Yaesoubi R, Trotter C, Colijn C, et al. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: a transmission dynamic modeling study. <em>PLoS Med</em> 2018;15(1):e1002495-e1002495.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1371/journal.pmed.1002495" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29364884/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423818400016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+cost-effectiveness+of+alternative+vaccination+strategies+for+polyvalent+meningococcal+vaccines+in+Burkina+Faso%3A+a+transmission+dynamic+modeling+study.&amp;publication_year=2018&amp;journal=PLoS+Med&amp;pages=e1002495-e1002495&amp;doi=10.1371%2Fjournal.pmed.1002495&amp;pmid=29364884" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Arifin SMN, Zimmer C, Trotter C, et al. Cost-effectiveness of alternative uses of polyvalent meningococcal vaccines in Niger: an agent-based transmission modeling study. <em>Med Decis Making</em> 2019;39:553-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1177/0272989X19859899" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31268405/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000476280600001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cost-effectiveness+of+alternative+uses+of+polyvalent+meningococcal+vaccines+in+Niger%3A+an+agent-based+transmission+modeling+study.&amp;publication_year=2019&amp;journal=Med+Decis+Making&amp;pages=553-567&amp;doi=10.1177%2F0272989X19859899&amp;pmid=31268405" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Loma Linda, California</span></div><div><span>Surgery, Plastic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883936/academic-plastic-surgeon-microsurgery-opportunity-in-southern-california/?query=fjwp&amp;rid=69418">Academic Plastic Surgeon - Microsurgery Opportunity in Southern California</a></div></div><div class="nejm-widget_item"><div><span> Florida</span></div><div><span>Neurology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/885124/exciting-neurology-opportunities-with-baycare-medical-group/?query=fjwp&amp;rid=903">Exciting Neurology Opportunities with BayCare Medical Group</a></div></div><div class="nejm-widget_item"><div><span> Ithaca, New York</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/887493/dermatology-ithaca-ny-/?query=fjwp&amp;rid=899">Dermatology (Ithaca, NY)</a></div></div><div class="nejm-widget_item"><div><span> Massachusetts</span></div><div><span>Medical Genetics</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/876545/medical-genetics-division-chief-at-baystate-health/?query=fjwf&amp;rid=705">Medical Genetics Division Chief at Baystate Health</a></div></div><div class="nejm-widget_item"><div><span> Danville, Pennsylvania</span></div><div><span>Emergency Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883599/emergency-radiology-onsite-or-remote/?query=fjwf&amp;rid=764">Emergency Radiology - Onsite or Remote</a></div></div><div class="nejm-widget_item"><div><span> Butte, Montana</span></div><div><span>Urology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883732/physician-urology/?query=fjwf&amp;rid=751">Physician Urology</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2013615&amp;pubId=41290143&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d683a4e0d7a511-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d683a4e0d7a511-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d683a4e0d7a511-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$162652427$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$162652427$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$162652427$--></div></div><div class="mlt-body"><!--?lit$162652427$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$162652427$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$162652427$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$162652427$-->Jan 23, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1901229?query=recirc_Semantic" target="_self">Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England</a></div><div class="mlt-article-authors"><!--?lit$162652427$-->S.N. Ladhani and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$162652427$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$162652427$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$162652427$-->Sep 16, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2035916?query=recirc_Semantic" target="_self">Safety and Efficacy of a Typhoid Conjugate Vaccine in Malawian Children</a></div><div class="mlt-article-authors"><!--?lit$162652427$-->P.D. Patel and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$162652427$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$162652427$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$162652427$-->May 25, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2214924?query=recirc_Semantic" target="_self">Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia</a></div><div class="mlt-article-authors"><!--?lit$162652427$-->F.C. Haidara and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$162652427$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$162652427$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$162652427$-->Feb 02, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2206433?query=recirc_Semantic" target="_self">Effectiveness of a Meningococcal Group B Vaccine (4CMenB) in Children</a></div><div class="mlt-article-authors"><!--?lit$162652427$-->J. Castilla and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$162652427$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$162652427$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$162652427$-->May 25, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2301698?query=recirc_Semantic" target="_self">Global Control of Meningococcal Disease</a></div><div class="mlt-article-authors"><!--?lit$162652427$-->D.S. Stephens</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2013615?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2013615" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2013615.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2013615"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Meningococcal Serogroup ACWYX Conjugate Vaccine in Malian Toddlers</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2034442" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2104882" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2013615_f1.jpg"><img src="/cms/10.1056/NEJMoa2013615/asset/d0e5fe79-1afa-427e-8eb0-f919689733a0/assets/images/large/nejmoa2013615_f1.jpg" height="1140" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Geometric Mean Titers of Serum Bactericidal Antibody, According to Meningococcal Serogroup (Per-Protocol Population).</div><div class="notes"><div role="doc-footnote">Shown are the geometric mean titers and 95% confidence intervals (𝙸 bars) of the serum bactericidal antibody with baby rabbit complement that were observed in participants who received nonadjuvanted NmCV-5, adjuvanted NmCV-5, or MenACWY-D at baseline (day 0), at 28 days and 84 days after receipt of the first dose (days 28 and 84), and at 28 days after receipt of the second dose (day 112). The per-protocol population included all the participants who correctly received their assigned trial vaccine with no major protocol deviations that were determined to potentially interfere with the immunogenicity assessment of the trial vaccines and who provided, at least at one time point after vaccination, a serum sample that could be evaluated.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Participants with Serum Bactericidal Antibody Titers of at Least 128 at Days 0, 28, 84, and 112 (Per-Protocol Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Participants with an Increase in Serum Bactericidal Antibody Titers of at Least 4 Times the Baseline Value on Days 28 and 112 (Per-Protocol Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/384/22" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 384 No. 22</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 03, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2034442" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.F. Bajorin and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 03, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2104882" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Brief Report: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">N.H. Schultz and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jun 03, 2021</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2101897" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.P. Whitlock and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2013615%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2013615&amp;pubId=41290143&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2013615%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2013615&amp;pubId=41290143&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05502414628073177" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d683a4e0d7a511-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d683a4e0d7a511-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d683a4e0d7a511-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d683a4e0d7a511-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d683a4e0d7a511-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d683a4e0d7a511-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d683a4e0d7a511-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d683a4e0d7a511-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d683a4e0d7a511-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d683a4e0d7a511-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d683a4ca5ea511',t:'MTc0OTUzMzgxOS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d683a4ca5ea511&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-transactionid="9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" id="captureIFrame_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" target="captureIFrame_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="capture_screen"><input id="capture_signIn_js_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="js_version"><input id="capture_signIn_transactionId_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" type="hidden" class="capture_transactionId_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="capture_transactionId"><input id="capture_signIn_form_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="form"><input id="capture_signIn_flow_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="flow"><input id="capture_signIn_client_id_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="client_id"><input id="capture_signIn_redirect_uri_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="redirect_uri"><input id="capture_signIn_response_type_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="response_type"><input id="capture_signIn_flow_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="flow_version"><input id="capture_signIn_settings_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="settings_version"><input id="capture_signIn_locale_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="locale"><input id="capture_signIn_recaptcha_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_9gixgr8pynuzql7ppq878hx8wnbd4ei7zh0hxg9e" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2013615?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><axb-caamwvptmdky></axb-caamwvptmdky><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div></body></html>